Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 67 articles:
HTML format
Text format



Single Articles


    April 2017
  1. KHOURY HJ, Collins RH Jr, Blum W, Stiff PS, et al
    Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.
    Cancer. 2017 Apr 14. doi: 10.1002/cncr.30696.
    PubMed     Text format     Abstract available


  2. BATTIPAGLIA G, Ruggeri A, Massoud R, El Cheikh J, et al
    Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30680.
    PubMed     Text format     Abstract available


  3. BODDU PC, Kantarjian HM, Ravandi F, Garcia-Manero G, et al
    Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30704.
    PubMed     Text format     Abstract available


    March 2017
  4. NAGLER A, Labopin M, Beelen D, Ciceri F, et al
    Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Cancer. 2017 Mar 22. doi: 10.1002/cncr.30646.
    PubMed     Text format     Abstract available


  5. RYTTING ME, Jabbour EJ, O'Brien SM, Kantarjian HM, et al
    Acute lymphoblastic leukemia in adolescents and young adults.
    Cancer. 2017 Mar 22. doi: 10.1002/cncr.30624.
    PubMed     Text format     Abstract available


    February 2017
  6. KONG JH, Winton EF, Heffner LT, Chen Z, et al
    Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Cancer. 2017 Feb 27. doi: 10.1002/cncr.30608.
    PubMed     Text format     Abstract available


  7. QU X, Othus M, Davison J, Wu Y, et al
    Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.
    Cancer. 2017 Feb 21. doi: 10.1002/cncr.30626.
    PubMed     Text format     Abstract available


  8. PAVLU J, Labopin M, Zoellner AK, Sakellari I, et al
    Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT.
    Cancer. 2017 Feb 17. doi: 10.1002/cncr.30604.
    PubMed     Text format     Abstract available


  9. LAUSEKER M, Hasford J, Saussele S, Kremers S, et al
    Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.
    Cancer. 2017 Feb 13. doi: 10.1002/cncr.30636.
    PubMed     Text format     Abstract available


  10. JAIN P, Thompson PA, Keating M, Estrov Z, et al
    Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30596.
    PubMed     Text format     Abstract available


    January 2017
  11. MICHELIS FV, Gupta V, Zhang MJ, Wang HL, et al
    Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
    Cancer. 2017 Jan 24. doi: 10.1002/cncr.30567.
    PubMed     Text format     Abstract available


  12. WEISDORF DJ, Millard HR, Horowitz MM, Hyare PS, et al
    Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.
    Cancer. 2017 Jan 24. doi: 10.1002/cncr.30536.
    PubMed     Text format     Abstract available


  13. NABBOUH AI, Hleihel RS, Saliba JL, Karam MM, et al
    Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
    Cancer. 2017 Jan 5. doi: 10.1002/cncr.30515.
    PubMed     Text format     Abstract available


    December 2016
  14. ROUSSELOT P, Prost S, Guilhot J, Roy L, et al
    Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30490.
    PubMed     Text format     Abstract available


  15. GORIN NC, Labopin M, Czerw T, Pabst T, et al
    Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the Eu
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30400.
    PubMed     Text format     Abstract available


    November 2016
  16. WAGNER B, da Silva Nardi F, Schramm S, Kraemer T, et al
    HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia.
    Cancer. 2016 Nov 2. doi: 10.1002/cncr.30427.
    PubMed     Text format     Abstract available


    October 2016
  17. KOLLER PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, et al
    Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
    Cancer. 2016 Oct 20. doi: 10.1002/cncr.30362.
    PubMed     Text format     Abstract available


  18. ISSA GC, Kantarjian HM, Yin CC, Qiao W, et al
    Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
    Cancer. 2016 Oct 3. doi: 10.1002/cncr.30376.
    PubMed     Text format     Abstract available


    September 2016
  19. ANTILLON FG, Blanco JG, Valverde PD, Castellanos M, et al
    The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results.
    Cancer. 2016 Sep 28. doi: 10.1002/cncr.30257.
    PubMed     Text format     Abstract available


  20. RAVANDI F, Jorgensen J, Borthakur G, Jabbour E, et al
    Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
    Cancer. 2016 Sep 22. doi: 10.1002/cncr.30361.
    PubMed     Text format     Abstract available


  21. MUFFLY L, Lichtensztajn D, Shiraz P, Abrahao R, et al
    Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.
    Cancer. 2016 Sep 13. doi: 10.1002/cncr.30322.
    PubMed     Text format     Abstract available


  22. JABBOUR E, Short NJ, Jorgensen JL, Yilmaz M, et al
    Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Cancer. 2016 Sep 7. doi: 10.1002/cncr.30264.
    PubMed     Text format     Abstract available


    August 2016
  23. ARCHER NP, Perez-Andreu V, Scheurer ME, Rabin KR, et al
    Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics.
    Cancer. 2016 Aug 16. doi: 10.1002/cncr.30241.
    PubMed     Text format     Abstract available


  24. CREUTZIG U, Zimmermann M, Reinhardt D, Rasche M, et al
    Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups.
    Cancer. 2016 Aug 16. doi: 10.1002/cncr.30220.
    PubMed     Text format     Abstract available


  25. TAKAHASHI K, Kantarjian HM, Yang Y, Sasaki K, et al
    A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.
    Cancer. 2016 Aug 10. doi: 10.1002/cncr.30197.
    PubMed     Text format     Abstract available


  26. SHORT NJ, Kantarjian HM, Sasaki K, Cortes JE, et al
    Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Cancer. 2016 Aug 10. doi: 10.1002/cncr.30262.
    PubMed     Text format     Abstract available


  27. SASAKI K, Jabbour EJ, Ravandi F, Short NJ, et al
    Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
    Cancer. 2016 Aug 1. doi: 10.1002/cncr.30231.
    PubMed     Text format     Abstract available


    July 2016
  28. KADIA TM, Jain P, Ravandi F, Garcia-Manero G, et al
    TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.
    Cancer. 2016 Jul 26. doi: 10.1002/cncr.30203.
    PubMed     Text format     Abstract available


    June 2016
  29. FREEMAN AT, Meyer AM, Smitherman AB, Zhou L, et al
    Statewide geographic variation in outcomes for adults with acute myeloid leukemia in North Carolina.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30139.
    PubMed     Text format     Abstract available


  30. GIDDINGS BM, Whitehead TP, Metayer C, Miller MD, et al
    Childhood leukemia incidence in California: High and rising in the Hispanic population.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30129.
    PubMed     Text format     Abstract available


  31. DEOL A, Sengsayadeth S, Ahn KW, Wang HL, et al
    Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30140.
    PubMed     Text format     Abstract available


  32. GIEBEL S, Czyz A, Ottmann O, Baron F, et al
    Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the acute leukemia working party of
    Cancer. 2016 Jun 16. doi: 10.1002/cncr.30130.
    PubMed     Text format     Abstract available


  33. BORTHAKUR G, Popplewell L, Boyiadzis M, Foran J, et al
    Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
    Cancer. 2016;122:1871-9.
    PubMed     Text format     Abstract available


  34. KAHN JM, Keegan TH, Tao L, Abrahao R, et al
    Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma.
    Cancer. 2016 Jun 10. doi: 10.1002/cncr.30089.
    PubMed     Text format     Abstract available


    May 2016
  35. THOMPSON PA, Stingo F, Keating MJ, Ferrajoli A, et al
    Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
    Cancer. 2016 May 16. doi: 10.1002/cncr.30069.
    PubMed     Text format     Abstract available


  36. FATHI AT, DeAngelo DJ, Stevenson KE, Kolitz JE, et al
    Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.
    Cancer. 2016 May 12. doi: 10.1002/cncr.30037.
    PubMed     Text format     Abstract available


  37. HAAVISTO A, Henriksson M, Heikkinen R, Puukko-Viertomies LR, et al
    Sexual function in male long-term survivors of childhood acute lymphoblastic leukemia.
    Cancer. 2016 May 12. doi: 10.1002/cncr.29989.
    PubMed     Text format     Abstract available


  38. KANTARJIAN HM, Stein AS, Bargou RC, Grande Garcia C, et al
    Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from two phase 2 studies.
    Cancer. 2016 May 3. doi: 10.1002/cncr.30031.
    PubMed     Text format     Abstract available


  39. GALLOWAY-PENA JR, Smith DP, Sahasrabhojane P, Ajami NJ, et al
    The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia.
    Cancer. 2016 May 3. doi: 10.1002/cncr.30039.
    PubMed     Text format     Abstract available


    April 2016
  40. AZUERO A
    A note on the magnitude of hazard ratios.
    Cancer. 2016;122:1298-9.
    PubMed     Text format    


  41. BORATE UM, Mineishi S, Costa LJ
    Reply to a note on the magnitude of hazard ratios.
    Cancer. 2016;122:1299-300.
    PubMed     Text format    


    March 2016
  42. KUNIN-BATSON AS, Lu X, Balsamo L, Graber K, et al
    Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study.
    Cancer. 2016 Mar 29. doi: 10.1002/cncr.29946.
    PubMed     Text format     Abstract available


  43. CZERW T, Labopin M, Gorin NC, Giebel S, et al
    Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the acute leukemia working party of the European Society for Blood and
    Cancer. 2016 Mar 28. doi: 10.1002/cncr.29990.
    PubMed     Text format     Abstract available


  44. SCHIFFER CA, Cortes JE, Hochhaus A, Saglio G, et al
    Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Cancer. 2016 Mar 21. doi: 10.1002/cncr.29933.
    PubMed     Text format     Abstract available


  45. BOSE P, Verstovsek S
    The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
    Cancer. 2016;122:681-92.
    PubMed     Text format     Abstract available


    February 2016
  46. TRICOLI JV, Blair DG, Anders CK, Bleyer A, et al
    Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.
    Cancer. 2016 Feb 5. doi: 10.1002/cncr.29871.
    PubMed     Text format     Abstract available


    January 2016
  47. DUPUIS LL, Lu X, Mitchell HR, Sung L, et al
    Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group.
    Cancer. 2016 Jan 15. doi: 10.1002/cncr.29876.
    PubMed     Text format     Abstract available


  48. LIPSHULTZ SE, Anderson LM, Miller TL, Gerschenson M, et al
    Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.
    Cancer. 2016 Jan 13. doi: 10.1002/cncr.29872.
    PubMed     Text format     Abstract available


    December 2015
  49. FALCHI L, Verstovsek S, Ravandi-Kashani F, Kantarjian HM, et al
    The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.
    Cancer. 2015 Dec 30. doi: 10.1002/cncr.29852.
    PubMed     Text format     Abstract available


  50. HAKIM H, Dallas R, Zhou Y, Pei D, et al
    Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia.
    Cancer. 2015 Dec 23. doi: 10.1002/cncr.29833.
    PubMed     Text format     Abstract available



  51. Recurrence, poor survival more likely in patients with acute myeloid leukemia who have certain mutations.
    Cancer. 2015;121:4275.
    PubMed     Text format    


  52. EL-JAWAHRI AR, Vandusen HB, Traeger LN, Fishbein JN, et al
    Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation.
    Cancer. 2015 Dec 9. doi: 10.1002/cncr.29818.
    PubMed     Text format     Abstract available


  53. CHURPEK JE, Marquez R, Neistadt B, Claussen K, et al
    Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
    Cancer. 2015 Dec 7. doi: 10.1002/cncr.29615.
    PubMed     Text format     Abstract available


  54. KARP JE, Wolff AC
    Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer.
    Cancer. 2015 Dec 7. doi: 10.1002/cncr.29613.
    PubMed     Text format    


    November 2015
  55. THOMPSON PA, O'Brien SM, Xiao L, Wang X, et al
    beta -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
    Cancer. 2015 Nov 20. doi: 10.1002/cncr.29794.
    PubMed     Text format     Abstract available


    October 2015
  56. SASAKI K, Kantarjian HM, Jain P, Jabbour EJ, et al
    Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
    Cancer. 2015 Oct 19. doi: 10.1002/cncr.29745.
    PubMed     Text format     Abstract available


    September 2015
  57. BORATE UM, Mineishi S, Costa LJ
    Nonbiological factors affecting survival in younger patients with acute myeloid leukemia.
    Cancer. 2015 Sep 14. doi: 10.1002/cncr.29436.
    PubMed     Text format     Abstract available


    August 2015
  58. RAVANDI F, O'Brien SM, Cortes JE, Thomas DM, et al
    Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Cancer. 2015 Aug 26. doi: 10.1002/cncr.29646.
    PubMed     Text format     Abstract available


  59. KO RH, Jones TL, Radvinsky D, Robison N, et al
    Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
    Cancer. 2015 Aug 26. doi: 10.1002/cncr.29641.
    PubMed     Text format     Abstract available


  60. ABRAHAO R, Ribeiro RC, Medeiros BC, Keogh RH, et al
    Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California.
    Cancer. 2015 Aug 11. doi: 10.1002/cncr.29631.
    PubMed     Text format     Abstract available


    July 2015
  61. SHORT NJ, Keating MJ, Wierda WG, Faderl S, et al
    Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
    Cancer. 2015 Jul 28. doi: 10.1002/cncr.29605.
    PubMed     Text format     Abstract available


  62. YILMAZ M, Lahoti A, O'Brien S, Nogueras-Gonzalez GM, et al
    Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Cancer. 2015 Jul 28. doi: 10.1002/cncr.29587.
    PubMed     Text format     Abstract available


  63. RIBERA J, Morgades M, Zamora L, Montesinos P, et al
    Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.
    Cancer. 2015 Jul 20. doi: 10.1002/cncr.29579.
    PubMed     Text format     Abstract available


  64. TASIAN SK, Loh ML, Hunger SP
    Childhood acute lymphoblastic leukemia: Integrating genomics into therapy.
    Cancer. 2015 Jul 20. doi: 10.1002/cncr.29573.
    PubMed     Text format     Abstract available


  65. THOMPSON PA, O'Brien SM, Wierda WG, Ferrajoli A, et al
    Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
    Cancer. 2015 Jul 20. doi: 10.1002/cncr.29566.
    PubMed     Text format     Abstract available


    June 2015
  66. GROSSO DA, Hess RC, Weiss MA
    Immunotherapy in acute myeloid leukemia.
    Cancer. 2015 Jun 10. doi: 10.1002/cncr.29378.
    PubMed     Text format     Abstract available


    May 2015
  67. GRONSETH CM, McElhone SE, Storer BE, Kroeger KA, et al
    Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia.
    Cancer. 2015 May 29. doi: 10.1002/cncr.29475.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: